Pharma Latch

Amplify your immune responses with Pharma Latch! If you are attending Society for Immunotherapy of Cancer (SITC) in Houston come and stop by our booth (743) to learn how intradermal delivery can amplify the immune response of your immunotherapies. The Pharma Latch platform simplifies and de-risks intradermal delivery enabling intradermal to be considered a realistic route of administration for the first time. Our devices can deliver a range of volumes and viscosities (up to: 3 ml, 60 cP) and can support your drug delivery journey from pre-clinical through to clinical studies! #SITC2024 #immunotherapies #cancervaccines #intradermal

Join us at Society for Immunotherapy of Cancer (SITC) in Houston! 📅 Date: November 6 – 10 📍 Location: Booth 743   We're excited to be exhibiting at SITC in Houston, where we’ll be showcasing our groundbreaking intradermal technology. Intradermal administration holds the potential to unlock the full therapeutic value of immunotherapies such as cancer vaccines, thanks to the immune-rich environment of the skin.   At Pharma Latch, we’ve developed the only intradermal platform that overcomes the limitations of traditional injection methods. Our technology ensures consistent and precise dose delivery (up to 3 mL, 60 cP) without leakage or spray-back—making the intradermal route simpler and more reliable for the pharmaceutical industry.   Our platform is designed to support the entire R&D lifecycle: from pre-clinical studies using the Pharma Latch Pico (small animal device) to patient applications with the Pharma Latch Hollow (PLH) and self-injector in development.   Our first device, the PLH, is a sterile-packaged, single-use medical device (Class II, FDA 510(k) pathway) currently in late-stage manufacturing in the USA. It is available for pre-clinical studies now, with clinical evaluations set for early 2025.   Visit us at Booth 743 to discover more about our technology and discuss how we can collaborate with you!   #CancerVaccines #Intradermal #MedicalDevice #SITC2024 #PharmaInnovation #Immunotherapy #EnablingTechnology

Great first day at the The World Vaccine Congress in Barcelona! A big thank you to everyone who visited our booth yesterday. If you haven’t had a chance yet, stop by Booth S32 to discover how intradermal is truly a realistic route of administration with Pharma Latch and how we can enable next generation vaccines! #VaccineInnovation #IntradermalDelivery #WVCEU2024

Delighted to have Adam Rock presenting at #PODD2024. if you're attending, please stop by our booth.

Great start to #PODD 2024! Come and stop by booth number 2 to learn how our unique technology is enabling intradermal delivery to be considered a realistic option to the pharmaceutical industry for the first time! Our colleague Adam Rock will be speaking this evening so be sure to drop in! 🕕 Track 5B, 6:22 pm

Discover how intradermal delivery with Pharma Latch is changing the future of vaccines at the The World Vaccine Congress in Barcelona!   📅 Date: October 28 - 31 📍 Location: Booth S32   The benefits of intradermal (ID) vaccine delivery are well established. By targeting the skin's abundant antigen-presenting cells, ID vaccination can amplify immune responses as well as achieve 5-10x dose-sparing without compromising efficacy. While the benefits are clear - adoption has been limited, due to the challenges of current delivery systems. That’s where Pharma Latch comes in. Our unique technology ensures simple and risk-free ID delivery by ensuring consistent penetration to the dermal layer—without leakage, spray back or user variability. We can also deliver high volumes and viscosities (up to 3 mL, 60 cP), which is groundbreaking for ID delivery! Our Pharma Latch Hollow device is a HCP-administered medical device with FDA 510k approval anticipated in early 2025. It's available now for pre-clinical evaluation. We also offer Pharma Latch Pico, a device tailored for small animal pre-clinical work, and we’re developing a range of self-administration devices based on this platform. Come visit us at Booth S32 to learn more and learn more about how intradermal delivery with Pharma Latch is the future of vaccines! #WVC2024 #VaccineInnovation #IntradermalDelivery #PharmaLatch #MedicalDevice

Great opening to PDA Arizona! Please come visit Ronan Byrne and Nicky Bertollo at booth 1014 to learn how Intradermal delivery is a truly realistic route of administration for the first time!

Discover the Intradermal Platform That Really Delivers at PODD: Partnership Opportunities in Drug Delivery Conference! 📅 Date: October 28 - 29 📍 Location: Booth 2   At Pharma Latch, we have developed the only ID platform that overcomes the limitations of traditional injection methods. Our technology ensures simple and consistent dose delivery (up to 3 mL, 60cP) without leakage or spray-back—and does not require drug reformulation. This simplifies the ID route, unlocking its potential for the pharmaceutical industry, for the first time.    Designed with pharma in mind, our platform supports your entire R&D process—from pre-clinical studies using the Pharma Latch Pico to patient applications with the Pharma Latch Hollow (PLH) and self-injector.     Our first device, the PLH, is a sterile-packaged, single-use medical device (Class II, FDA 510(k) pathway) currently in late-stage manufacturing in the USA. It is available for pre-clinical studies now, with clinical evaluations set for early 2025.    We look forward to connecting at PODD and discussing how we can advance drug delivery together! #Pharma #Intradermal #DrugDelivery #PODD2024 PODD: Partnership Opportunities in Drug Delivery Community News

Discover the only intradermal platform that really delivers at PDA - Parenteral Drug Association Arizona!   📅 Date: October 22 – 23 📍 Location: Booth 1014   We're excited to showcase our groundbreaking intradermal (ID) platform technology at the PDA - Parenteral Drug Association conference in Arizona!   At Pharma Latch, we’ve developed the only intradermal platform that really delivers. Our technology overcomes the challenges of traditional ID injection methods, providing precise, consistent dose delivery (up to 3 mL, 60cP) without leakage or spray-back, and no need for reformulation. This de-risks and simplifies the evaluation of the intradermal route, unlocking its potential as a viable option for the pharmaceutical industry.   Our platform is designed with pharma in mind, supporting your entire R&D journey—from preclinical studies in small animals using our Pharma Latch Pico to patient-applications with the Pharma Latch Hollow (PLH). The core of our platform is our revolutionary opposing arrays of hollow microneedles, engineered to overcome the challenges of ID injection. While this core technology remains the same, it can be customised into multiple device iterations—whether for animal studies, clinical applications, or advanced self-injectors—each tailored for specific needs and use cases.   The first device built on this platform, the Pharma Latch Hollow PLH, is a sterile, single-use medical device (Class II, FDA 510(k) pathway) currently in late-stage manufacturing in the USA. It’s available now for preclinical studies, with clinical evaluations set to begin in early 2025.   Looking forward to connecting with you at PDA Arizona and exploring how we can advance the future of drug delivery together! #Pharma #Intradermal #DrugDelivery #PDA2024

What an exciting first day at Festival of Biologics 2024! It’s been great connecting with so many people and sharing how Pharma Latch is revolutionising intradermal drug delivery. Stop by Booth S46 to learn how our intradermal platform technology offers game-changing advantages: stronger immune responses, dose-sparing, minimally invasive administration, and reduced systemic toxicity—key to advancing biologic therapies, especially immunotherapies. Don’t miss out, visit us at S46! #PharmaLatch #IntradermalDelivery #Biologics #Innovation #Immunotherapy